Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

Otsuka Holdings

大塚ホールディングス

4578 · TSE · Pharmaceutical · 9 articles

Financials Consolidated

Revenue¥2.47tn+6.0% year on yearConsolidated · FY12/25

Operating profit¥479bn+48.2% year on yearConsolidated · FY12/25

Net profit¥363bn+5.8% year on yearConsolidated · FY12/25

Dividend per share¥140.00FY12/25

Performance over time

Revenue
¥1.50tnFY12/21
¥1.74tnFY12/22
¥2.02tnFY12/23
¥2.33tnFY12/24
¥2.47tnFY12/25
Net profit (attributable)
¥125bnFY12/21
¥134bnFY12/22
¥122bnFY12/23
¥343bnFY12/24
¥363bnFY12/25
Op. cash flow
¥229bnFY12/21
¥212bnFY12/22
¥283bnFY12/23
¥355bnFY12/24
¥404bnFY12/25

People & pay

Employees, whole group37,758 peopleFY12/25

Employees, parent company (non-consolidated)224 peopleFY12/25

Average salary¥10.0mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOp. profitNet profit (attributable)EPSDividendTotal assetsTotal equityOp. cash flow
FY12/25¥2.47tn+6.0% year on year¥479bn¥363bn¥685.06¥140.00¥4.20tn¥3.10tn¥404bn
FY12/24¥2.33tn+15.4% year on year¥324bn¥343bn¥633.76¥120.00¥3.74tn¥2.78tn¥355bn
FY12/23¥2.02tn+16.1% year on year—¥122bn¥224.10¥110.00¥3.36tn¥2.44tn¥283bn
FY12/22¥1.74tn+16.0% year on year—¥134bn¥246.80¥100.00¥3.10tn—¥212bn
FY12/21¥1.50tn—¥125bn¥231.32¥100.00¥2.82tn—¥229bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XUA7 · IFRS, company-only figures: Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4578

Tokyo Brief coverage

Buybacks

Authorised and executed under the company’s current programmes.

1 programme · data through

The line marks how much of the buying window has passed; a bar beyond it is buying ahead of pace.

Buybacks
ResolutionProgress by companyFiling
Runs to 23 Dec 2026100% of yen limit used¥50bn / ¥50bn · 4.54m / 7m shares83% of the buying window to 23 Dec 2026 has passedFiled  — filing S100ZGN6

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

6 fiscal years · data through

Balance-sheet value
¥62.5bnFY12/21
¥50.7bnFY12/22
¥49.6bnFY12/23
¥50.4bnFY12/24
¥46.7bnFY12/25
Sale proceeds
¥5.7bnFY12/21
¥16.9bnFY12/22
¥2.6bnFY12/23
¥3.6bnFY12/24
¥0.9bnFY12/25

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 2025Largest holding subsidiary30¥46.7bn—16¥936mFiled  — filing S100XUA7
Show 5 more fiscal years (6 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Dec 2024Largest holding subsidiary43¥50.4bn—13¥3.6bnFiled  — filing S100VJ30
31 Dec 2023Largest holding subsidiary57¥49.6bn—11¥2.58bnFiled  — filing S100T6VU
31 Dec 2022Largest holding subsidiary66¥50.7bn—7¥16.9bnFiled  — filing S100QJ0T
31 Dec 2021Largest holding subsidiary70¥62.5bn—1¥5.73bnFiled  — filing S100NTB1
31 Dec 2020Largest holding subsidiary26¥6.6bn———Filed  — filing S100L3LV

Fund positioning

Current holdings disclosed by tracked funds.

25 funds · data through

Held by 25 tracked funds; largest weight 14.13%. Holdings as of 30 Jun 2026–20 Nov 2026.

Show 15 more funds (25 total)